Barclays PLC Has $4.37 Million Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Barclays PLC raised its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 19.1% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 39,210 shares of the specialty pharmaceutical company's stock after purchasing an additional 6,289 shares during the period. Barclays PLC owned 0.06% of Jazz Pharmaceuticals worth $4,369,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Wealth Enhancement Advisory Services LLC boosted its position in Jazz Pharmaceuticals by 27.6% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 3,551 shares of the specialty pharmaceutical company's stock valued at $379,000 after buying an additional 768 shares during the last quarter. AlphaCentric Advisors LLC grew its stake in Jazz Pharmaceuticals by 29.4% during the 2nd quarter. AlphaCentric Advisors LLC now owns 11,000 shares of the specialty pharmaceutical company's stock valued at $1,174,000 after purchasing an additional 2,500 shares in the last quarter. Allspring Global Investments Holdings LLC increased its holdings in Jazz Pharmaceuticals by 12.0% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 18,013 shares of the specialty pharmaceutical company's stock worth $1,923,000 after purchasing an additional 1,931 shares during the last quarter. AustralianSuper Pty Ltd raised its position in shares of Jazz Pharmaceuticals by 72.8% in the 2nd quarter. AustralianSuper Pty Ltd now owns 95,631 shares of the specialty pharmaceutical company's stock valued at $10,207,000 after purchasing an additional 40,302 shares in the last quarter. Finally, Burney Co. boosted its stake in shares of Jazz Pharmaceuticals by 1.9% during the 2nd quarter. Burney Co. now owns 19,823 shares of the specialty pharmaceutical company's stock valued at $2,116,000 after buying an additional 377 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,000 shares of the business's stock in a transaction on Friday, November 1st. The stock was sold at an average price of $110.84, for a total value of $110,840.00. Following the sale, the chief executive officer now owns 428,976 shares of the company's stock, valued at approximately $47,547,699.84. The trade was a 0.23 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Neena M. Patil sold 3,700 shares of the company's stock in a transaction on Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the sale, the executive vice president now owns 33,048 shares of the company's stock, valued at approximately $4,078,453.68. This trade represents a 10.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 6,753 shares of company stock worth $816,289 in the last 90 days. Corporate insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ traded up $0.12 on Friday, hitting $122.97. The company's stock had a trading volume of 1,767,343 shares, compared to its average volume of 675,822. The company has a market capitalization of $7.43 billion, a price-to-earnings ratio of 17.32, a price-to-earnings-growth ratio of 1.02 and a beta of 0.57. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $134.17. The stock's 50-day moving average is $118.89 and its two-hundred day moving average is $112.84.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. HC Wainwright restated a "buy" rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $140.00 target price on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. Piper Sandler restated an "overweight" rating and set a $163.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Morgan Stanley raised shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and boosted their price objective for the company from $140.00 to $175.00 in a research report on Thursday, December 12th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $179.00 target price on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. Two investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Jazz Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $177.00.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.